"THE PT WITH HISTORY OF DIABETES, SMOKING, HYPERTENSION (HTN) AND KIDNEY FAILURE WAS NOT REPORTED TO BE IMMUNOCOMPROMISED OR HAVE A HISTORY OF BLOOD-CLOTTING DISORDERS. PT WAS ADMITTED FOR AN ELECTIVE PROCEDURE WITH DIAGNOSIS OF PREVIOUS MYOCARDIAL INFARCTION (MI) AND CONGESTIVE HEART FAILURE (CHF). THE TARGET LESION WAS THE PROXIMAL LEFT ANTERIOR DESCENDING (LAD). THE VESSEL WAS REPORTED TO BE NATIVE CORONARY, NOT TORTUOUS, AND 3.2 MM IN DIAMETER. THE LESION WAS REPORTED TO BE: ECCENTRIC AND BIFURCATED, DE NOVO, NOT CALCIFIED, ABSENT OF THROMBUS, 21.3 MM IN LENGTH, AND CLASSIFIED AS A TYPE C LESION. THE LESION WAS PRE-DILATED WITH A 3.0 X 20 MM BALLOON AT 8ATM FOR 30 SECONDS. A CYPHER 3.5 X 23MM STENT WAS IMPLANTED AT 10ATM FOR 30 SECONDS. THE STENT WAS POST-DILATED WITH A 3.0 X 20 MM BALLOON AT 14ATM FOR 21 SECONDS. IVUS WAS NOT DONE. THE PRE-PROCEDURE % STENOSIS WAS UNKNOWN AND THE RESIDUAL STENOSIS AFTER THE PROCEDURE WAS 25%. THE FLOW PRE AND POST-PROCEDURE WAS TIMI 3. THERE WAS GOOD WALL APPOSITION AND NO POSSIBILITY OF DISSECTION REPORTED. HEPARIN 10,000 UNITS WAS GIVEN. AN ACT WAS NOT MEASURED. ANTIPLATELET THERAPY WAS: ASPIRIN 100 MG/DAY, AND TICLID 200 MG/DAY. THE PT WAS REPORTED TO HAVE BEEN COMPLIANT. THE ADVERSE EVENT (AE) REPORTED WAS A LATE THROMBOSIS THAT OCCURRED APPROXIMATELY FORTY-FIVE DAYS AFTER THE INDEX PROCEDURE. THE PT WAS RETURNED TO THE HOSPITAL IN CARDIOPULMONARY ARREST. CARDIOPULONARY RESUSCITATION (CPR) WAS CONDUCTED WHILE BRINGING THE PT INTO THE CATH LAB. UNDER PERCUTANEOUS CARDIOPULMONARY SUPPORT, CORONARY ANGIOGRAPHY WAS CONDUCTED AND THROMBUS WAS FOUND IN THE CYPHER AND PROXIMAL TO IT. THE TREATMENT FOR THE THROMBOSIS WAS ASPIRATION, POBA, AND AN ADDITIONAL UNKNOWN STENT. TWO DAYS POST-INTERVENTION THE PT EXPIRED. NO AUTOPSY REPORT WAS AVAILABLE. THE PHYSICIAN COMMENTED THAT THE CAUSE THE THROMBOSIS WAS POSSIBLY DUE TO UNDERDEPLOYMENT OF THE CYPHER STENT. HE USUALLY INFLATES THE CYPHER AT 15-16 ATM BUT DURING THIS PROCEDURE IT WAS 10ATMS. PLEASE NOTE THAT DEVICE IS DISTRIBUTED OUTSIDE THE UNITED STATES; HOWEVER IT IS SIMILAR TO THE UNITED STATES PRODUCT. THE PRODUCT IS NOT AVAILABLE FOR EVALUATION AND TESTING.
LATE THROMBOSIS/DEATH POST CYPHER STENT IMPLANTATION."
